RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

They are a private company whose main programs are in hypertension and diabetes. Alzheimer's is down the list, and in discovery phase. The key people came from Bristol-Myers and Squibb. Their main claim to fame is a technology for rationally designing molecules that they hope gives them an edge. But they are pursuing BACE inhibitors, not a empty field by any means. Boehringer Ingelheim likes to partner with companies in early-stage (e.g. Evotec),and then co-develop. This fits their modus operandi.

Anticipating two questions: Yes, they are aware of Cortex. Why would they go with this instead? They are interested in disease-modification in AD, and at least one BACE inhibitor made it through Phase I OK without (known) adverse event issues (CoMentis and Astellas). Which is not something that can be said for high-impact AMPA drugs at this point.

NeuroInvestment